Global Major Histocompatibility Complex (MHC) Tetramer Market Strategic Research Report

Scope of the Report

The global Major Histocompatibility Complex (MHC) Tetramer market size is predicted to grow from US$ 13.32 million in 2025 to US$ 22.66 million in 2032; it is expected to grow at a CAGR of 8.0% from 2026 to 2032.

An MHC tetramer is a laboratory tool used to study antigen-specific T cells. It consists of four major histocompatibility complex (MHC) molecules bound to a specific peptide and labeled with a fluorescent tag. These tetramers can bind to T cell receptors (TCRs) on the surface of T cells that recognize the specific peptide-MHC complex. By using flow cytometry, researchers can identify and quantify antigen-specific T cells, making MHC tetramers a valuable tool for immunological studies, including vaccine development, cancer immunotherapy, and infectious disease research.

In 2023, North America accounted for the largest sales share of the MHC tetramer market. The region is characterized by a large number of pharmaceutical R&D service providers. Meanwhile, Asia Pacific is expected to witness the highest CAGR during the forecast period.

The major global companies of Major Histocompatibility Complex (MHC) Tetramer include MBL Life Science, ProImmune, BioLegend, KACTUS, Creative Biolabs, immunAware, HELIXGEN, ACROBiosystems and etc. In 2023, the world's top three vendors accounted for approximately 56.50% of the revenue.

In terms of application, the continued research demand for cancer immunotherapy and adoptive T cell therapy and immune responses to emerging and re-emerging viral infectious diseases such as COVID-19, HIV and influenza is the main reason driving the MHC tetramer market. In 2023, MHC tetramers for cancer research accounted for approximately 48.00% of the market.

Currently, the MHC tetramer market mainly consists of two types: MHC-I and MHC-II. MHC-I is mainly used for research on cancer, viruses, bacteria, etc., and MHC-II is mainly used for research on viruses, bacteria, allergens, etc. In 2023, the sales of MHC-I and MHC-II will be US$6.63 million and US$4.29 million, respectively.

The Major Histocompatibility Complex (MHC) Tetramer market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Market segmentation

Major Histocompatibility Complex (MHC) Tetramer market is split by Type and by Application. For the period 2026-2032, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by regions, regional analysis covers

North America

Europe

Asia-Pacific (China, Japan, South Korea, Rest of Asia)

South America

Middle East & Africa

This report presents a comprehensive overview of the global Major Histocompatibility Complex (MHC) Tetramer market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type,

• MHC-I
• MHC-II

Segment by players, this report covers

• MBL Life Science
• ProImmune
• BioLegend
• KACTUS
• Creative Biolabs
• immunAware
• HELIXGEN
• ACROBiosystems

Segment by Application

• Cancer research
• Virus research
• Bacteria research
• Other

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Major Histocompatibility Complex (MHC) Tetramer market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Cancer research, Virus research, Bacteria research evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact